Cargando…

Prognostic and predictive value of Ki-67 in triple-negative breast cancer

This study was to investigate the prognostic role of Ki-67 in further classification of triple negative breast cancer (TNBC), and to test whether high expression level of Ki67 can predict benefit from carboplatin. From January 2004 to December 2012, 363 patients operated for TNBC were identified thr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Wei, Wu, Jiayi, Zhang, Peifeng, Fei, Xiaochun, Zong, Yu, Chen, Xiaosong, Huang, Ou, He, Jian-Rong, Chen, Weiguo, Li, Yafen, Shen, Kunwei, Zhu, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058740/ https://www.ncbi.nlm.nih.gov/pubmed/27145269 http://dx.doi.org/10.18632/oncotarget.9075

Ejemplares similares

Progesterone Receptor Status and Ki-67 Index May Predict Early Relapse in Luminal B/HER2 Negative Breast Cancer Patients: A Retrospective Study
por: Zong, Yu, et al.
Publicado: (2014)

Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients
por: Chen, Xiaosong, et al.
Publicado: (2015)

Clinical validation of Ki67 by quantitative reverse transcription-polymerase chain reaction (RT-PCR) in HR+/HER2- early breast cancer
por: Gao, Weiqi, et al.
Publicado: (2019)

Presence of CHD1L Over-Expression Is Associated with Aggressive Tumor Biology and Is a Novel Prognostic Biomarker for Patient Survival in Human Breast Cancer
por: Wu, Jiayi, et al.
Publicado: (2014)

A Novel Prognostic Scoring System Integrating Gene Expressions and Clinicopathological Characteristics to Predict Very Early Relapse in Node-Negative Estrogen Receptor-Positive/HER2-Negative Breast Cancer
por: Lin, Caijin, et al.
Publicado: (2020)

Ki67 increase after core needle biopsy associated with worse disease outcome in HER2-negative breast cancer patients
por: Tong, Yiwei, et al.
Publicado: (2023)

The prognostic and predictive potential of Ki-67 in triple-negative breast cancer
por: Zhu, Xiuzhi, et al.
Publicado: (2020)

Changes of Tumor Infiltrating Lymphocytes after Core Needle Biopsy and the Prognostic Implications in Early Stage Breast Cancer: A Retrospective Study
por: Huang, Jiahui, et al.
Publicado: (2019)

Sonography with vertical orientation feature predicts worse disease outcome in triple negative breast cancer
por: Wang, Haoyu, et al.
Publicado: (2019)

Targeting cancer-associated adipocyte-derived CXCL8 inhibits triple-negative breast cancer progression and enhances the efficacy of anti-PD-1 immunotherapy
por: Huang, Renhong, et al.
Publicado: (2023)

Prognostic Value of Ki-67 in Patients With Resected Triple-Negative Breast Cancer: A Meta-Analysis
por: Wu, Qiang, et al.
Publicado: (2019)

Targeting glutamine metabolic reprogramming of SLC7A5 enhances the efficacy of anti-PD-1 in triple-negative breast cancer
por: Huang, Renhong, et al.
Publicado: (2023)

Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients
por: Wu, Jiayi, et al.
Publicado: (2017)

A senescence-associated signature refines the classification of different modification patterns and characterization of tumor immune microenvironment infiltration in triple-negative breast cancer
por: Huang, Renhong, et al.
Publicado: (2023)

New insights into the prognostic value of Ki-67 labeling index in patients with triple-negative breast cancer
por: Hao, Shuang, et al.
Publicado: (2016)

Clinicopathological Features and Disease Outcome in Breast Cancer Patients with Hormonal Receptor Discordance between Core Needle Biopsy and Following Surgical Sample
por: Zhu, Siji, et al.
Publicado: (2019)

Biologic behavior and long-term outcomes of breast ductal carcinoma in situ with microinvasion
por: Fang, Yan, et al.
Publicado: (2016)

Overexpression of epithelial growth factor receptor (EGFR) predicts better response to neo-adjuvant chemotherapy in patients with triple-negative breast cancer
por: Tang, Yiqing, et al.
Publicado: (2012)

Molecular Subtype May Be More Associated With Prognosis and Chemotherapy Benefit Than Tumor Size in T1N0 Breast Cancer Patients: An Analysis of 2,168 Patients for Possible De-Escalation Treatment
por: Zhu, Siji, et al.
Publicado: (2021)

Association of Ki-67 Change Pattern After Core Needle Biopsy and Prognosis in HR+/HER2− Early Breast Cancer Patients
por: Li, Shuai, et al.
Publicado: (2022)

P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients
por: Pan, Yunbao, et al.
Publicado: (2017)

The prognostic relevance of p53 and Ki-67 to chemotherapy sensitivity and prognosis in triple-negative breast cancer
por: Zhang, Guojing, et al.
Publicado: (2021)

Association of Molecular Biomarker Heterogeneity With Treatment Pattern and Disease Outcomes in Multifocal or Multicentric Breast Cancer
por: Li, Shuai, et al.
Publicado: (2022)

Prognostic value of Ki-67 in nasopharyngeal carcinoma: a meta-analysis
por: Li, Yulin, et al.
Publicado: (2021)

Ki67 as a predictor of poor prognosis in patients with triple-negative breast cancer
por: LI, HAITAO, et al.
Publicado: (2015)

HER2 positivity is not associated with adverse prognosis in high-risk estrogen receptor-positive early breast cancer patients treated with chemotherapy and trastuzumab
por: Li, Shuai, et al.
Publicado: (2020)

Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients
por: Li, Shuai, et al.
Publicado: (2021)

Prognostic Value of Ki67 in Patients with Stage 1–2 Endometrial Cancer: Validation of the Cut-off Value of Ki67 as a Predictive Factor
por: Jiang, Peng, et al.
Publicado: (2020)

A high absolute lymphocyte count predicts a poor prognosis in HER-2- positive breast cancer patients treated with trastuzumab
por: Hong, Jin, et al.
Publicado: (2019)

Primary 21-Gene Recurrence Score and Disease Outcome in Loco-Regional and Distant Recurrent Breast Cancer Patients
por: Lu, Yujie, et al.
Publicado: (2020)

Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21-gene recurrence score of 26–30
por: Yu, Jing, et al.
Publicado: (2020)

Early response and pathological complete remission in Breast Cancer with different molecular subtypes: a retrospective single center analysis
por: Hong, Jin, et al.
Publicado: (2020)

21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes
por: Tong, Yiwei, et al.
Publicado: (2019)

IGF-1 Interacted With Obesity in Prognosis Prediction in HER2-Positive Breast Cancer Patients
por: Tong, Yiwei, et al.
Publicado: (2020)

Do 21-Gene Recurrence Score Influence Chemotherapy Decisions in T1bN0 Breast Cancer Patients?
por: Yu, Jing, et al.
Publicado: (2020)

A nomogram to predict the high-risk RS in HR+/HER2-breast cancer patients older than 50 years of age
por: Yu, Jing, et al.
Publicado: (2021)

The impact of surgical excision of the primary tumor in stage IV breast cancer on survival: a meta-analysis
por: Lu, Shuangshuang, et al.
Publicado: (2017)

Preoperative core needle biopsy is accurate in determining molecular subtypes in invasive breast cancer
por: Chen, Xiaosong, et al.
Publicado: (2013)

Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin
por: Wang, Ruo-Xi, et al.
Publicado: (2016)

A Prognostic Model for Triple-Negative Breast Cancer Patients Based on Node Status, Cathepsin-D and Ki-67 Index
por: Huang, Liang, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_vbk5o4lm4flatntq45955c2bu1